Literature DB >> 28670714

Cervical cancer incidence after up to 20 years of observation among women with HIV.

L Stewart Massad1, Nancy A Hessol2, Teresa M Darragh3, Howard Minkoff4, Christine Colie5, Rodney L Wright6, Mardge Cohen7, Eric C Seaberg8.   

Abstract

To estimate the incidence of invasive cervical cancer (ICC) across up to 21 years of follow-up among women with human immunodeficiency virus (HIV) and to compare it to that among HIV-uninfected women, we reviewed ICC diagnoses from a 20-year multi-site U.S. cohort study of HIV infected and uninfected women who had Pap testing every 6 months. Incidence rates were calculated and compared to those in HIV-negative women. Incidence ratios standardized to age-, sex-, race-, and calendar-year specific population rates were calculated. After a median follow-up of 12.3 years, four ICCs were confirmed in HIV seropositive women, only one in the last 10 years of observation, and none in seronegative women. The ICC incidence rate did not differ significantly by HIV status (HIV seronegative: 0/100,000 person-years vs. HIV seropositive: 19.5/100,000 person-years; p = 0.53). The standardized incidence ratio for the HIV-infected WIHS participants was 3.31 (95% CI: 0.90, 8.47; p = 0.07). Although marginally more common in women without HIV, for those with HIV in a prevention program, ICC does not emerge as a major threat as women age.
© 2017 UICC.

Entities:  

Keywords:  HIV in women; cancer prevention; cervical cancer

Mesh:

Year:  2017        PMID: 28670714      PMCID: PMC5760214          DOI: 10.1002/ijc.30866

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

Review 1.  The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench.

Authors:  Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

2.  Excess cancers among HIV-infected people in the United States.

Authors:  Hilary A Robbins; Ruth M Pfeiffer; Meredith S Shiels; Jianmin Li; H Irene Hall; Eric A Engels
Journal:  J Natl Cancer Inst       Date:  2015-02-06       Impact factor: 13.506

3.  Incidence of invasive cervical cancer in a cohort of HIV-seropositive women before and after the introduction of highly active antiretroviral therapy.

Authors:  M Dorrucci; B Suligoi; D Serraino; U Tirelli; G Rezza
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-01       Impact factor: 3.731

4.  Adherence to colposcopy among women with HIV infection.

Authors:  H E Cejtin; E Komaroff; L S Massad; A Korn; J B Schmidt; D Eisenberger-Matiyahu; E Stier
Journal:  J Acquir Immune Defic Syndr       Date:  1999-11-01       Impact factor: 3.731

5.  The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women.

Authors:  H Minkoff; L Ahdieh; L S Massad; K Anastos; D H Watts; S Melnick; L Muderspach; R Burk; J Palefsky
Journal:  AIDS       Date:  2001-11-09       Impact factor: 4.177

6.  Spectrum of cancer risk late after AIDS onset in the United States.

Authors:  Edgar P Simard; Ruth M Pfeiffer; Eric A Engels
Journal:  Arch Intern Med       Date:  2010-08-09

7.  Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort.

Authors:  Mira Hleyhel; Aurélien Belot; Anne Marie Bouvier; Pierre Tattevin; Jérôme Pacanowski; Philippe Genet; Nathalie De Castro; Jean-Luc Berger; Caroline Dupont; Armelle Lavolé; Christian Pradier; Dominique Salmon; Anne Simon; Valérie Martinez; Dominique Costagliola; Sophie Grabar
Journal:  Clin Infect Dis       Date:  2013-07-29       Impact factor: 9.079

8.  Squamous cervical lesions in women with human immunodeficiency virus: long-term follow-up.

Authors:  L Stewart Massad; Eric C Seaberg; Rodney L Wright; Teresa Darragh; Yi-Chun Lee; Christine Colie; Robert Burk; Howard D Strickler; D Heather Watts
Journal:  Obstet Gynecol       Date:  2008-06       Impact factor: 7.661

9.  Knowledge of cervical cancer prevention and human papillomavirus among women with HIV.

Authors:  L Stewart Massad; Charlesnika T Evans; Tracey E Wilson; Johanna L Goderre; Nancy A Hessol; Donna Henry; Christine Colie; Howard D Strickler; Alexandra M Levine; D Heather Watts; Kathleen M Weber
Journal:  Gynecol Oncol       Date:  2010-01-27       Impact factor: 5.482

10.  Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women.

Authors:  Howard Minkoff; Ye Zhong; Robert D Burk; Joel M Palefsky; Xiaonan Xue; D Heather Watts; Alexandra M Levine; Rodney L Wright; Christine Colie; Gypsyamber D'Souza; L Stewart Massad; Howard D Strickler
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

View more
  3 in total

1.  Cancer Risk in Older Persons Living With Human Immunodeficiency Virus Infection in the United States.

Authors:  Parag Mahale; Eric A Engels; Anna E Coghill; Amy R Kahn; Meredith S Shiels
Journal:  Clin Infect Dis       Date:  2018-06-18       Impact factor: 9.079

2.  Veteran Women Living With Human Immunodeficiency Virus Have Increased Risk of Human Papillomavirus (HPV)-Associated Genital Tract Cancers.

Authors:  Eva Clark; Liang Chen; Yongquan Dong; Suchismita Raychaudhury; Donna White; Jennifer R Kramer; Elizabeth Chiao
Journal:  Clin Infect Dis       Date:  2021-05-04       Impact factor: 9.079

3.  Cervical cancer incidence stratified by age in women with HIV compared with the general population in the United States, 2002-2016.

Authors:  Elizabeth A Stier; Eric Engels; Marie-Josèphe Horner; William T Robinson; Baozhen Qiao; Jennifer Hayes; Rana Bayakly; Bridget J Anderson; Lou Gonsalves; Karen S Pawlish; Diego Zavala; Analise Monterosso; Meredith S Shiels
Journal:  AIDS       Date:  2021-09-01       Impact factor: 4.632

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.